Introduction
Nuclear medicine in 2024 stands at the intersection of innovation and challenge, signaling a transformative era for this critical field of healthcare. With unprecedented strides in radiopharmaceutical development, groundbreaking clinical advancements, and significant investment from pharmaceutical giants, the discipline has gained renewed momentum in its quest to enhance diagnostic precision and therapeutic efficacy. Yet alongside these achievements come complex challenges, including supply chain constraints, regulatory hurdles, and the imperative for scalable production to meet growing demand. These dynamics highlight the dual narrative of progress and adaptation shaping nuclear medicine today.
The past year has marked a pivotal period of technological breakthroughs and strategic acquisitions that underscore the sector’s rising prominence in oncology and beyond. From the emergence of actinium-225 (Ac-225) as a game-changer in targeted alpha therapies to the expansion of production facilities for critical radioisotopes like lutetium-177 (Lu-177) and lead-212 (Pb-212), the field is rapidly evolving. Simultaneously, regulatory milestones and clinical trial results reflect the promise and complexities of bringing innovative therapies to market. As nuclear medicine continues to expand its footprint, the developments of 2024 lay the foundation for a future where this specialized branch of medicine could redefine patient outcomes across a range of diseases.
As nuclear medicine advances into 2025, the field faces an array of challenges that will require coordinated efforts to overcome. Supply chain limitations for critical radioisotopes, such as Ac-225 and Lu-177, remain a pressing issue, threatening the continuity of clinical trials and the scalability of production. Additionally, the high costs associated with radiopharmaceutical development and manufacturing pose significant barriers to patient access, highlighting the need for innovative funding and pricing strategies. Regulatory complexities continue to evolve as more advanced therapies reach clinical stages, necessitating clearer pathways to approval and harmonized global standards. Furthermore, ensuring safety in clinical applications—especially in patient selection and monitoring—will be paramount as the field addresses setbacks from earlier trials. Tackling these challenges will be crucial for sustaining momentum and ensuring that the groundbreaking potential of nuclear medicine translates into widespread clinical benefits.
Jump to a section:
Key Trends Driving the Nuclear Medicine Market
Radiopharmaceutical M&A Boom
In 2024, the nuclear medicine sector saw an unparalleled surge in radiopharmaceutical development and investment as the potential of targeted radiotherapy became increasingly recognized across the pharmaceutical and biotech industries. This growing interest prompted a wave of acquisitions, strategic partnerships, and funding initiatives aimed at advancing the field. Companies were eager to tap into the power of radiopharmaceuticals to offer more precise and effective treatments for cancer and other diseases, leading to a flurry of activity focused on developing innovative therapies.
These investments not only fuel the advancement of novel radiopharmaceuticals but also enhance the production capabilities required to meet the increasing demand. The combination of financial backing and collaborative efforts propels the sector toward a future where radiotherapy plays a central role in transforming patient care, particularly in oncology.
Key examples of significant investments and acquisitions in the radiopharmaceutical sector in
2024 include:
- Acquisition of Fusion Pharmaceuticals by AstraZeneca: AstraZeneca’s $2 billion acquisition strengthened its position in targeted alpha therapies, focusing on difficult-to-treat cancers. This acquisition allows AstraZeneca to enhance its capabilities in developing novel radiopharmaceuticals that target specific cancer cells, offering a promising new approach to precision medicine in oncology.
- Bristol Myers Squibb’s $4.1 billion bid for RayzeBio: By acquiring RayzeBio, Bristol Myers Squibb gained access to a promising pipeline of radiopharmaceuticals, including RYZ101, its lead candidate for treating gastroenteropancreatic neuroendocrine tumors. This acquisition reflects the growing focus on using targeted therapies to treat rare and challenging cancers, with the goal to improve outcomes for patients with limited treatment options.
- Novartis’ $1 billion acquisition of Mariana Oncology: Novartis expanded its radiopharmaceutical portfolio with a $1 billion acquisition of Mariana Oncology, particularly boosting its presence in the development of Ac-225-based therapies.
- Eli Lilly’s $60 million upfront payment to Aktis Oncology: Eli Lilly entered into a partnership with Aktis Oncology, paying $60 million upfront to support the development of therapeutic and diagnostic products.
- Eli Lilly’s $140 million deal with Radionetics Oncology: Eli Lilly also struck a $140 million deal with Radionetics Oncology to advance GPCR-targeted radiopharmaceutical drugs. These drugs are designed to target specific receptors on cancer cells, enhancing the precision and effectiveness of radiotherapy treatments while minimizing damage to healthy tissues. This partnership marks a significant step toward more effective and personalized cancer therapies.
These acquisitions and partnerships highlight the increasing interest and investment in radiopharmaceuticals as a vital area of growth within oncology, with the potential to revolutionize cancer treatment.
Focus on Alpha Emitters
Ac-225 has firmly established itself as a leading candidate in the rapidly advancing field of targeted alpha therapy, due to its potential to offer highly localized, effective treatment for a variety of cancers. Known for its ability to deliver powerful radiation directly to cancer cells while sparing surrounding healthy tissue, Ac-225 is gaining significant attention from pharmaceutical companies and researchers alike. As a result, companies have made numerous investments and formed strategic partnerships to develop and scale Ac-225-based therapies, particularly for cancers that are resistant to traditional treatments, such as prostate and small cell lung cancer. These developments highlight Ac-225’s transformative role in the future of cancer therapy.
Notable developments in Ac-225 this year include:
- Bayer’s supply agreement with PanTera for Ac-225: Bayer entered into a supply agreement with PanTera to secure Ac-225 starting in the second half of 2024. This agreement is crucial for ensuring the consistent availability of high-quality Ac-225, which is essential for the ongoing development of targeted alpha therapies. Bayer’s commitment underscores the growing demand for this radioisotope and highlights its potential in the development of next-generation cancer treatments.
- Full-Life Technologies receiving FDA Fast Track designation for 225Ac-FL-020: Full-Life Technologies achieved a significant milestone with the Food and Drug Administration (FDA) Fast Track designation for their Ac-225-based compound 225Ac-FL-020, designed to treat metastatic castration-resistant prostate cancer (mCRPC). This designation accelerates the regulatory review process, providing Full-Life Technologies with an expedited pathway to bring their promising therapy to patients. The recognition highlights the growing interest in Ac-225 as a powerful tool in the fight against prostate cancer.
- Abdera Therapeutics receiving FDA Fast Track designation for ABD-147: Abdera Therapeutics’ Ac-225-based therapy ABD-147 received FDA Fast Track designation for targeting DLL3 in small cell lung cancer . DLL3 is a protein expressed in high levels on small cell lung cancer cells, making it an ideal target for precision therapy. The Fast Track designation expedites the clinical development of ABD147, providing hope for improved outcomes in patients with this aggressive and difficult-to-treat cancer.
- NorthStar’s agreement to provide high-purity Ac-225 to Ariceum Therapeutics: NorthStar Medical Radioisotopes entered an agreement to supply Ariceum Therapeutics with non-carrieradded, high-purity Ac-225 for clinical use. This collaboration ensures that Ariceum will have access to highquality Ac-225 for the development of its targeted therapies. High purity Ac-225 is essential for ensuring the efficacy and safety of radiopharmaceuticals, making this agreement a critical step in advancing clinical trials and potential therapies.
These developments exemplify the significant momentum behind Ac-225 as a leading contender in targeted alpha therapy, with a focus on advancing treatment options for difficult-to-treat cancers. The continued investment and regulatory progress signal that Ac-225 could play a pivotal role in the future of precision oncology.
Expansion of Production Facilities
As the demand for radiopharmaceuticals continues to rise, particularly in cancer treatment, the expansion of production facilities has become a critical focus for companies aiming to meet the growing needs of the healthcare sector. With the increasing adoption of targeted therapies and the widespread interest in isotopes like Lu-177, Ac-225, and Pb-212, the capacity to produce these radioisotopes at scale is essential to ensure timely access to life-saving treatments. As a result, companies are heavily investing in both the development of new facilities and the enhancement of existing ones, positioning themselves to play a key role in the future of nuclear medicine.
Significant expansions in radioisotope production in 2024 include:
- Novartis’ opening of its advanced radioligand therapy manufacturing facility in Indianapolis: Novartis unveiled its largest and most advanced radioligand therapy manufacturing facility in Indianapolis, dedicated to the production of Pluvicto®, a radiopharmaceutical used in the treatment of prostate cancer. This state-of-the-art facility aims to address the increasing demand for radioligand therapies and streamline the production process, ensuring a steady supply of high-quality treatment options for cancer patients worldwide. The facility represents a significant step in Novartis’ commitment to expanding its presence in the radiopharmaceutical market.
- Orano Med’s groundbreaking of a €250 million plant in France for Pb-212 production: Orano Med announced the groundbreaking of a new €250 million production plant in France, designed specifically for the manufacturing of Pb-212. Pb-212 is a highly promising radioisotope for targeted alpha therapy, particularly in the treatment of cancers that are resistant to conventional therapies. This new facility will significantly increase production capacity, enabling Orano Med to meet the growing demand for Pb-212-based treatments and contribute to the development of cutting-edge therapies for patients with difficult-to-treat cancers.
- ITM’s announcement of the Nova Facility for Lu-177 production: ITM, a leader in the production of radiopharmaceuticals, announced the operational readiness of its Nova Facility, which is set to become the world’s largest Lu-177 production site. Lu-177 is a critical radioisotope used in the treatment of various cancers, including neuroendocrine tumors. This facility will play a key role in scaling up production of Lu-177, ensuring that it is available at the scale needed to meet global demand and support the increasing number of patients receiving targeted radiation therapies.
- Isotopia Molecular Imaging’s opening of a non-carrier-added Lu-177 production site in
Seibersdorf, Austria: Isotopia Molecular Imaging opened a new production site in Seibersdorf, Austria, dedicated to the manufacturing of non-carrier-added Lu-177. This advanced facility aims to provide high-purity Lu-177 for use in targeted radiotherapy, particularly for cancers that benefit from this isotope’s precision. The facility’s opening is a strategic move to increase production capacity and support the growing need for Lu-177 in radioligand therapies, ensuring that high-quality isotopes are available for clinical use across Europe and beyond. - Full-Life Technologies’ unveiling of its Belgium facility for Ac-225 production: Full-Life Technologies revealed footage of its new facility in Belgium, designed for GMP-level production of Ac-225 radioisotopes and radiolabeled drug products. Ac-225 is emerging as a key component of targeted alpha therapy, and this new facility is poised to play a crucial role in scaling production to meet the rising demand for Ac-225-based therapies. The GMP-level facility ensures that the radiopharmaceuticals produced meet the highest safety and quality standards, advancing Full-Life’s role in providing cutting-edge cancer treatments.
These expansions are vital to addressing the increasing global demand for radiopharmaceuticals in 2025 and beyond, ensuring that companies are equipped to meet both the current and future needs of the healthcare sector. The continued development of such production facilities highlights the industry’s commitment to bringing innovative, life-saving therapies to patients in need.
Advancements in Theranostics
In 2024, theranostics—the combination of diagnostic and therapeutic radiopharmaceuticals—emerged as one of the most promising areas of innovation in nuclear medicine. By pairing imaging agents with targeted therapies, theranostics enables doctors to both detect and treat cancers more precisely. This integrated approach not only enhances the accuracy of diagnoses but also optimizes therapeutic outcomes by ensuring that radiation is delivered directly to the cancer cells, sparing healthy tissue. Several companies are advancing this field with cutting-edge agents, showing great potential for transforming cancer treatment and improving patient outcomes.
Notable theranostics related developments this year include:
- Telix Pharmaceuticals’ proof-of-concept study for TLX592: Telix Pharmaceuticals completed a successful proof-of-concept study for TLX592, a targeted alpha therapy for prostate cancer. TLX592 uses Copper-64 (Cu-64) as a diagnostic imaging agent, allowing clinicians to visualize tumors before administering the corresponding alpha therapy. This approach enables a highly targeted treatment that maximizes the effectiveness of the therapy while minimizing damage to surrounding healthy tissue, paving the way for more personalized and effective prostate cancer treatment.
- Clarity Pharmaceuticals’ advancement of the SECuRE trial: Clarity Pharmaceuticals advanced its SECuRE trial, which is using Copper 67 (Cu-67)-based SAR-bisPSMA for both imaging and therapy in prostate cancer. This dual-purpose agent allows for precise imaging of cancerous tissues, followed by targeted radiation therapy. By using Cu-67, which has favorable physical properties for both imaging and therapy, Clarity’s approach aims to improve the efficacy of prostate cancer treatment, offering a promising option for patients with advanced or metastatic prostate cancer.
- PeptiDream’s development of PD-29875 for gastric cancer: PeptiDream announced the development of a new radiopharmaceutical candidate, PD-29875, which targets Claudin 18.2, a protein overexpressed in gastric cancer cells. This compound uses a combination of Ac-225 for targeted therapy and Cu-64 for diagnostic imaging. The dual approach enhances both the detection and treatment of gastric cancer, offering a potential breakthrough for patients with this challenging and often late-diagnosed cancer type.
These advancements demonstrate the growing potential of theranostics to revolutionize cancer care, providing more personalized and effective treatment options. By combining the power of diagnostics and therapeutics, these companies are at the forefront of a new era in precision oncology.
Major Advancements in 2024
- FDA approval of Flyrcado (Flurpiridaz F 18) for coronary artery disease diagnosis: GE Healthcare’s Flyrcado™, a PET radiotracer, received FDA approval in September 2024 for the enhanced diagnosis of coronary artery disease. This approval marks a major milestone in the use of nuclear medicine for non-invasive heart disease diagnostics. Flyrcado improves the accuracy of detecting coronary artery disease, potentially leading to better treatment decisions and outcomes for patients with heart conditions.
- FDA Breakthrough Therapy designations for AlphaMedix: RadioMedix and Orano Med received FDA Breakthrough Therapy designation for their Pb-212-based therapy, AlphaMedix™, designed for treating gastroenteropancreatic neuroendocrine tumors. This designation accelerates the clinical development of AlphaMedix, offering hope for improved treatment options for patients suffering from these rare and difficult-to-treat tumors.
- Convergent Therapeutics’ Phase II trial for CONV01-α: Convergent Therapeutics made progress with the dosing of the first patient in its Phase II CONVERGE-01 trial, which evaluates CONV01-α (Ac-225 rosopatamab tetraxetan) for PSMA-positive mCRPC. This marks a promising step forward in Ac-225-based therapies, with the potential to significantly improve treatment outcomes for prostate cancer patients.
- FDA clearance for Full-Life Technologies’ 225Ac-FL-020: Full-Life Technologies received FDA clearance for its Investigational New Drug application for 225Ac-FL-020, a radiopharmaceutical aimed at treating mCRPC. This clearance propels the company’s progress toward advancing Ac-225-based therapies, offering new hope for patients with advanced prostate cancer.
- Novartis’ expansion of Lutathera’s indication: Novartis received FDA approval for the label expansion of Lutathera® (lutetium Lu 177 dotatate), which broadens its application to include more neuroendocrine tumors. This approval represents a major advancement in the use of Lu-177 for targeted therapy, providing an important treatment option for patients with various forms of neuroendocrine tumors.
- Perspective Therapeutics’ [212Pb]VMT-α-NET phase I/IIa results: Perspective Therapeutics’ Phase I/IIa results for [212Pb]VMT-α-NET demonstrated a favorable safety profile and disease control in eight out of nine patients with neuroendocrine tumors. These results highlight Pb-212’s potential in targeted alpha therapy, offering promising outcomes for patients with challenging neuroendocrine tumors.
Clinical Trial Setbacks in 2024
Despite significant advances, 2024 also saw some major clinical trial setbacks that underscored the complexities of developing radiopharmaceuticals. These challenges, ranging from patient safety concerns to supply chain issues, highlight the need for rigorous clinical protocols and careful management as the field continues to evolve.
Key setbacks in 2024 include:
- Johnson & Johnson’s radiopharmaceutical trial setback: Johnson & Johnson’s early-stage trial for a prostate cancer radiopharmaceutical faced a major setback when four patient deaths occurred, and 37% of participants experienced serious treatment-emergent adverse events. This outcome underscores the risks associated with powerful targeted therapies, emphasizing the need for careful patient selection, robust monitoring, and clear understanding of potential adverse effects when developing new treatments.
- RayzeBio’s ACTION-1 trial halt due to actinium shortage: RayzeBio temporarily halted new patient enrollment in its ACTION-1 Phase III study due to a shortage of actinium, an essential isotope for their targeted radiopharmaceuticals. This incident highlights ongoing supply chain challenges in the radiopharmaceutical industry, where the availability of key isotopes like actinium can directly impact the progression of clinical trials and, ultimately, the development of life-saving therapies.
These setbacks serve as critical reminders of the complexities involved in radiopharmaceutical development, where unforeseen challenges can delay progress and impact patient outcomes. However, they also present opportunities for the industry to learn, adapt, and refine processes to ensure that such therapies reach patients
safely and effectively.
Other Notable Developments in Nuclear Medicine
2024 saw significant advancements in the use of Lu-177 and Pb-212 in radiopharmaceuticals, with several key developments that have the potential to expand treatment options for cancer patients. These isotopes are at the forefront of targeted therapies that use radiation to precisely target cancer cells, minimizing damage to healthy tissue. The progress made this year reinforces the growing importance of these therapies in precision oncology.
Key developments in therapies include:
- Novartis’ FDA approval for Lutathera expansion: Novartis received FDA approval for the label expansion of Lutathera, broadening its indication to treat additional types of neuroendocrine tumors. This expansion enhances Lutathera’s role as a critical therapy for patients with advanced neuroendocrine cancers, offering more treatment options for a challenging group of cancers. The approval reflects the growing confidence in the efficacy of Lu-177 as a targeted therapy for precision treatment.
- Blue Earth Therapeutics’ promising results with 177Lu-rhPSMA-10.1: Blue Earth Therapeutics reported promising preclinical results for its 177Lu-rhPSMA-10.1, a Lu-177-based radiopharmaceutical for prostate cancer treatment. These results suggest that 177Lu-rhPSMA-10.1 has the potential to provide effective, targeted radiation therapy for prostate cancer, especially in cases where traditional therapies have limited success. This advancement signifies a step forward in the use of Lu-177 for prostate cancer, expanding the potential therapeutic applications of this isotope.
- ARTBIO and Eckert & Ziegler partnership for Pb-212 conjugates: ARTBIO and Eckert & Ziegler announced a manufacturing and supply partnership for Pb-212 conjugates, aimed at accelerating the development of Pb-212-based therapies. This collaboration seeks to address the growing demand for Pb-212 in targeted therapies and streamline the production process, ensuring that high-quality conjugates are available for clinical use. The partnership is expected to enhance the development of Pb-212-based treatments, further establishing Pb-212 as a key player in the radiopharmaceutical landscape.
These advancements in Lu-177 and Pb-212 therapies underscore the ongoing evolution of targeted treatments in cancer care, marking significant steps toward more personalized, effective, and less invasive therapeutic options for patients.
Key Challenges and What to Expect in 2025
The field of nuclear medicine made significant strides in 2024, but several challenges are expected to persist into 2025. As the industry continues to evolve, overcoming these hurdles will be crucial to ensure that nuclear medicine can realize its full potential in treating cancer and other diseases. From supply chain disruptions to regulatory hurdles, the coming year will require sustained innovation and collaboration to address these challenges effectively.
1. Supply Chain Issues
- Limited production facilities: Despite new investments in production facilities, the number of sites capable of producing rare isotopes like Ac-225 remains limited, making supply vulnerable to bottlenecks.
- Growing demand: With an increasing number of radiopharmaceuticals entering clinical trials and gaining approval, demand for isotopes will continue to outpace supply.
- Geopolitical factors: The production of isotopes is concentrated in a few countries, meaning political instability, trade disruptions, or natural disasters in these regions could significantly impact global supply chains.
The shortage of Ac-225 that halted RayzeBio’s trial in 2024 serves as a reminder that other trials may face similar delays if supply issues persist.
2. Safety Concerns
- Complex dosimetry: Determining the optimal dose for individual patients while minimizing side effects requires sophisticated imaging and dosimetry techniques. As radiopharmaceutical treatments become more common, accurate dosing will remain a critical challenge.
- Long-term effects: As more patients undergo radiopharmaceutical treatments, monitoring for long-term side effects, including potential secondary cancers, will be increasingly important.
- Combination therapies: The use of radiopharmaceuticals alongside other cancer treatments, such as immunotherapy, could increase the risk of toxicity, necessitating more extensive research into safe combinations.
The deaths reported in Johnson & Johnson’s prostate cancer trial underscore the need for vigilant safety protocols and patient monitoring in the development of radiopharmaceuticals.
3. Regulatory Hurdles
- Increased scrutiny: As more radiopharmaceuticals enter clinical trials, regulators are expected to impose more stringent requirements for safety and efficacy data to ensure patient safety.
- Harmonization challenges: Disparities in regulatory standards between regions (such as the FDA in the US and the European Medicines Agency in Europe) may slow the global rollout of new therapies.
- Adapting to novel modalities: With new radiopharmaceutical therapies such as alpha-emitters and theranostics, regulatory agencies will need to develop and refine pathways for approval to accommodate these innovations.
The Breakthrough Therapy designation awarded to AlphaMedix signals growing recognition of
radiopharmaceuticals’ potential but also highlights the need for specialized regulatory frameworks
4. Manufacturing Scalability
- Capital-intensive infrastructure: Establishing and operating radioisotope production facilities requires significant investment. With growing demand, the challenge will be to scale production without compromising quality.
- Skilled workforce shortage: The highly specialized nature of radiopharmaceutical production means there may be a shortage of qualified personnel, potentially limiting the speed of expansion.
- Just-in-time logistics: Many radioisotopes have short half-lives, requiring precise, time-sensitive logistics for delivery and use, which could strain existing infrastructure.
Novartis’ new state-of-the-art facility in Indianapolis is an important step in expanding production capacity, but similar investments will be needed to meet growing demand.
5. Reimbursement and Access
- High costs: The complexity of producing radiopharmaceuticals, including the synthesis of isotopes and the radiolabeling process, leads to high treatment costs, making reimbursement a critical issue.
- Inadequate reimbursement models: Current reimbursement systems may not be well-equipped to handle the unique challenges of radiopharmaceutical therapies, potentially limiting patient access.
- Geographic disparities: Access to radiopharmaceuticals is often concentrated in specialized centers, meaning patients in rural or underserved areas may not benefit from these therapies.
Recent Centers for Medicare and Medicaid Services policy changes on the reimbursement for certain diagnostic radiopharmaceuticals represent a step forward, but similar policies will be necessary for therapeutic radiopharmaceuticals in 2025.
6. Technological Advancements
- Rapid obsolescence: As technology in nuclear medicine progresses at a rapid pace, investments in facilities and equipment may become outdated quickly, requiring constant upgrades.
- Data management: The increasing integration of AI and big data in nuclear medicine necessitates robust data management solutions to handle the vast amounts of patient data generated while ensuring privacy.
- Integration with other modalities: Combining radiopharmaceuticals with other therapies such as immunotherapy or chemotherapy will require new clinical trial designs, making integration a complex but essential focus.
As new radioisotopes and targeting molecules are developed, the infrastructure for production and imaging must adapt quickly to accommodate these advancements.
7. Competitive Landscape
- Market saturation: As more companies develop radiopharmaceuticals for similar indications, the market may become saturated, leading to increased competition and potentially diminishing the commercial viability of certain therapies.
- Intellectual property disputes: With the rapid growth of the radiopharmaceutical market, patent disputes over intellectual property are expected to rise, potentially delaying the development of new products.
- Consolidation: Larger pharmaceutical companies may continue acquiring smaller radiopharmaceutical firms, which could lead to consolidation and shift innovation dynamics in the industry.
Bristol Myers Squibb’s acquisition of RayzeBio for $4.1 billion highlights the competitive nature of the radiopharmaceutical market and the high value placed on innovative companies and technologies.
Conclusion
While 2024 has been a transformative year, in 2025, companies must address these critical challenges and build on the progress made. The convergence of scientific innovation in radiochemistry, molecular biology, and imaging technologies promises to yield even more precise and effective therapies. However, overcoming these challenges will require continued collaboration between the pharmaceutical industry, regulatory bodies, and healthcare providers to ensure that nuclear medicine can reach its full potential in treating a wide range of cancers and other diseases. With careful planning and strategic investment, the nuclear medicine landscape in 2025 will feature companies overcoming these hurdles, driving further breakthroughs and patient access to life-saving treatments.
Author:
Akash Nayak Karopadi,
Principal, Management Consulting Division
Author:
Akash Nayak Karopadi,
Principal, Management Consulting Division
Subscribe to our newsletter for the latest news, events, and thought leadership